Principles of Kinase Inhibitor Therapy for Solid Tumors.

about

Advances of small molecule targeting of kinases.Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

P2860

Q39450797-248BEE31-01A0-464D-8FCB-232116C90F82 Q50067311-E9B6EFED-1CB9-40E9-AED5-3EFD908D7751

P2860

Principles of Kinase Inhibitor Therapy for Solid Tumors.

Item

http://www.wikidata.org/entity/Q38802154

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Principles of Kinase Inhibitor Therapy for Solid Tumors.

@en

type

Item

label

Principles of Kinase Inhibitor Therapy for Solid Tumors.

@en

prefLabel

Principles of Kinase Inhibitor Therapy for Solid Tumors.

@en

P1476

Principles of Kinase Inhibitor Therapy for Solid Tumors

@en

P2093

Ronald P DeMatteo

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

The protein kinase complement of the human genome

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A landscape of driver mutations in melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

311-319

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0000000000001740

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P50

Teresa S Kim

Noah A Cohen

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27058947

http://www.w3.org/2001/XMLSchema#string

P932

5199628

http://www.w3.org/2001/XMLSchema#string

Principles of Kinase Inhibitor Therapy for Solid Tumors.

about

P2860

P2860

Principles of Kinase Inhibitor Therapy for Solid Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932